CORRECTION article

Front. Oncol., 27 June 2023

Sec. Cancer Molecular Targets and Therapeutics

Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1218746

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer

  • 1. Department of Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China

  • 2. Department of Gynecology, Tangshan People’s Hospital, Tangshan, China

  • 3. Department of Histoplasty and Embryology, Hebei Medical University, Shijiazhuang, China

  • 4. Department of Molecular Biology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China

  • 5. Department of gastrointestinal surgery, Tangshan People’s Hospital, Tangshan, China

  • 6. Department of Pathology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China

In the published article, there was an error in the Funding statement. The Grant number for the Natural Science Foundation of Hebei Province was displayed as “H20202063”. The correct Funding statement appears below.

The correct Funding statement is “This work was supported by grants from the Natural Science Foundation of Hebei Province (Grant number: H2020206385).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

advanced epithelial ovarian cancer, PARP1, cytokeratin, platinum resistance, prognosis

Citation

Zuo W-W, Zhao C-F, Li Y, Sun H-Y, Ma G-M, Liu Y-P and Kang S (2023) Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer. Front. Oncol. 13:1218746. doi: 10.3389/fonc.2023.1218746

Received

08 May 2023

Accepted

16 May 2023

Published

27 June 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2023

Updates

Copyright

*Correspondence: Shan Kang,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics